Monoclonal antibodies

Antibodies attacking virus
#Antibody discovery workflow #B cell diversity #Monoclonal antibodies

Last chance to register: How to accelerate antibody discovery

Download the webinar Accessing Broad B Cell Diversity to Rapidly Identify High-Value Rabbit Monoclonal Antibodies. Opto B Discovery on the Beacon optofluidic system is designed to enable rapid selection of lead candidates by function-forward screening of B cells in under one week. Anupam Singhal, Director of Product Management,… Read More

Webinar date:
Brought to you by Berkeley Lights
#Editor's Choice #News

IgE antibody
#Allergy #Antibody discovery workflow #Engineered antibodies #Genomics #IgE antibodies #Immunotherapy #Monoclonal antibodies

The power of IgE antibodies in creating novel therapeutics

Watch the webinar Harnessing the power of IgE antibodies to create novel therapeutics supported by SPT Labtech. From human B cells to engineered antibodies, IgGenix is taking a novel approach towards breaking through the last frontier of immunology: allergies. By reengineering key antibodies in the allergic cascade, this… Read More

Webinar date:
Brought to you by SPT Labtech
#News

Antibodies
#Antibody discovery workflow #B cell diversity #Monoclonal antibodies

Learn how to accelerate antibody discovery: webinar

Download the exclusive event: Accessing Broad B Cell Diversity to Rapidly Identify High-Value Rabbit Monoclonal Antibodies. Opto B Discovery on the Beacon optofluidic system is designed to enable rapid selection of lead candidates by function-forward screening of B cells in under one week. Anupam Singhal, Director of… Read More

Webinar date:
Brought to you by Berkeley Lights
#Editor's Choice #News

Heart attack patient with doctor
#Heart attack #Monoclonal antibodies #Phase II trial

UK trial will test new mAb treatment in heart attack patients

A potential new drug to improve the long-term outcomes for heart attack patients will be trialled in the UK under a new agreement.  The Phase IIb LIBERATE study will test the tolerance and the efficacy of glenzocimab 1000mg to reduce heart damage following a myocardial infarction (MI). Read More

#News

IgE antibodies
#Allergy #Antibody discovery workflow #Engineered antibodies #Genomics #IgE antibodies #Immunotherapy #Monoclonal antibodies

Learn how to harness the power of IgE antibodies

Watch the webinar Harnessing the power of IgE antibodies to create novel therapeutics supported by SPT Labtech. From human B cells to engineered antibodies, IgGenix is taking a novel approach towards breaking through the last frontier of immunology: allergies. By reengineering key antibodies in the allergic cascade, this… Read More

Webinar date:
Brought to you by SPT Labtech
#News

Antibodies
#Antibody discovery workflow #B cell diversity #Monoclonal antibodies

Exclusive webinar: how to accelerate antibody discovery

Download the exclusive free event: Accessing Broad B Cell Diversity to Rapidly Identify High-Value Rabbit Monoclonal Antibodies. Opto B Discovery on the Beacon optofluidic system is designed to enable rapid selection of lead candidates by function-forward screening of B cells in under one week. Anupam Singhal, Director… Read More

Webinar date:
Brought to you by Berkeley Lights
#Editor's Choice #News

IgE antibodies
#Allergy #Antibody discovery workflow #Engineered antibodies #Genomics #IgE antibodies #Immunotherapy #Monoclonal antibodies

Harnessing the power of IgE antibodies to create novel therapeutics

Watch the webinar Harnessing the power of IgE antibodies to create novel therapeutics supported by SPT Labtech. From human B cells to engineered antibodies, IgGenix is taking a novel approach towards breaking through the last frontier of immunology: allergies. By reengineering key antibodies in the allergic cascade, this biotech… Read More

Webinar date:
Brought to you by SPT Labtech
#News

#Antibody discovery workflow #B cell diversity #Monoclonal antibodies

How to accelerate the discovery of novel antibodies for drug discovery

Download the exclusive free webinar: Accessing Broad B Cell Diversity to Rapidly Identify High-Value Rabbit Monoclonal Antibodies. Opto B Discovery on the Beacon optofluidic system is designed to enable rapid selection of lead candidates by function-forward screening of B cells in under one week. Anupam Singhal, Director… Read More

Webinar date:
Brought to you by Berkeley Lights
#Editor's Choice #News

Monoclonal antibodies
#Cancer #Cancer immunotherapy #Cancer research #Monoclonal antibodies #Oncology #Phase I trial

Phase I trial of lead antibody candidate launched

DynamiCure has dosed the first patients in its Phase I clinical trial evaluating the first of the company’s two anti-CD93 monoclonal antibody candidates, DCBY02, in adults with a wide range of advanced cancers.  CD93 is a novel target downstream of VEGF-A (vascular endothelial growth factor) that has been shown… Read More

#Cancer Research #News

#Covid-19 #Covid-19 vaccine #Drug development #Drug discovery #Gene therapy #Geographic atrophy #Malaria #Monoclonal antibodies #Psychedelics #Treatment-resistant depression

This week in drug discovery (31 October – 4 November)

News round-up for 31 October – 4 November by DDW Digital Content Editor Diana Spencer  In a week that saw magic mushrooms making the headlines in the UK, we also reported on exciting potential new therapies for geographic atrophy and malaria prevention. Meanwhile, the quest to understand… Read More

#News

Mosquito against yellow background
#Malaria #Monoclonal antibodies #National Institute of Allergy and Infectious Diseases #Phase II trial #Sub-Saharan Africa

Monoclonal antibody could transform malaria prevention

One dose of an antibody drug safely protected healthy, non-pregnant adults from malaria infection during an intense six-month malaria season in Mali, Africa.   The antibody was up to 88.2% effective at preventing infection over a 24-week period, demonstrating for the first time that a monoclonal antibody can… Read More

#News #Trending News

#Biomarkers #Cancer research #Click chemistry #Covid-19 #Drug development #Drug discovery #Epstein-Barr virus #Monoclonal antibodies #mRNA #Oncology #Our Future Health #Pancreatic cancer

This week in drug discovery (24-28 October)

News round-up for 24-28 October by DDW Digital Content Editor Diana Spencer  Over the last seven days we’ve seen discoveries that could lead to new treatments for Covid-19, pancreatic cancer and Epstein-Barr virus, as well as the launch of the UK’s largest health research programme and the innovative application of… Read More

#News

Epstein-Barr Virus
#Drug development #Drug discovery #Epstein-Barr virus #Monoclonal antibodies #National Institute of Allergy and Infectious Diseases

Experimental monoclonal antibodies block EBV infection

A panel of investigational monoclonal antibodies (mAbs) targeting different sites of the Epstein-Barr virus (EBV) have been shown to block infection when tested in human cells in a laboratory setting.  One of the experimental mAbs provided nearly complete protection against EBV infection and lymphoma when tested in… Read More

#News

Antibodies attacking cancer cell
#Bispecific Antibodies #Cancer research #Cancer treatment #Mergers and acquisitions #Monoclonal antibodies #Oncology

Jazz acquires rights to HER2-targeted bispecific antibody

Under an exclusive agreement, Jazz Pharmaceuticals will acquire development and commercialisation rights to Zymeworks’ zanidatamab across all indications and all territories except for those Asia/Pacific territories previously licensed by Zymeworks. Zymeworks will receive a $50 million upfront payment, a second payment of $325 million, at Jazz’s option, and further potential… Read More

#Cancer Research #News

Cat in a box
#Allergen immunotherapy #Allergy #Monoclonal antibodies

Combination treatment could be more effective for cat allergy

New research has shown that standard cat allergy treatment can be enhanced to make it more effective and faster acting, and the benefits last for a year after treatment ends. These results show for the first time that adding a cytokine inhibitor to allergy shots could reduce allergic rhinitis symptoms… Read More

#News #Trending News

eBook cover
#Antibody-based therapeutics #Drug development #Monoclonal antibodies

Efficiently develop antibody-based therapeutics

In the Quality by Design (QbD) approach to antibody-based therapeutics development, stability characterisation —the probability of a protein unfolding or denaturing— is performed to ensure that structure and function are preserved throughout development and manufacturing.  Antibodies are affected by many factors along their journey to become therapeutics. Read More

#Resources